Satyaprasad. B, S. Jayakumari
firstname.lastname@example.org , email@example.com
Satyaprasad. B, S. Jayakumari
Department of Pharmacognosy, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies. (VISTAS), Pallavaram, Chennai-117, Tamilnadu, India.
Volume - 14,
Issue - 3,
Year - 2021
Resistance to antibiotics is a worldwide ongoing issue. Urgent want for brand new antibacterial agents has resulted in substantial studies efforts, with new molecules proposed for use in clinical practice. This review focuses on novel FDA approved antibacterial drugs (2018-2019): are new players in the area of resistant microorganism treatment. Omadacycline Sarecycline, Eravacycline, Plazomicin (2018-2019) are new healing options. This review focuses on novel FDA approved antibacterial agents (2018- 2019): are new players in the field of resistant bacteria treatment. Omadacycline is a modernized tetracycline with broad-spectrum activity designed to overcome tetracycline resistance. Eravacycline is a synthetic fluorocycline antibiotic belonging to the tetracycline drug class.It disrupts bacterial protein synthesis by binding the 30S ribosomal subunit, Sarecycline is a new first-in-class tetracycline-derived antibiotic indicated for adults and children aged 9 years and older with non-nodular moderate-to-severe acne vulgaris, Plazomicin has been engineered to overcome aminoglycoside-modifying enzymes, the most common amino glycoside-resistance mechanism in Enterobacteriaceae. Despite of these new developments, there is an ongoing need and urgency to develop novel antibiotic strategies and drugs to overrun the bacterial resistance to antibiotics. Many potential signs are being investigated, broadened and confirmed by future studies. Despite recent progress, it is imperative that new antibiotic drugs and new strategies be developed to com bat antibiotic resistance.
Cite this article:
Satyaprasad. B, S. Jayakumari. Novel Antimicrobial Drugs Omadacycline Sarecycline, Eravacycline, and Plazomicin: A Review. Research J. Pharm. and Tech. 2021; 14(3):1755-1759. doi: 10.5958/0974-360X.2021.00312.7
1. US Food and Drug Administration Novel Drug Approvals for 2018. [(accessed on 24 February 2019)].
2. Aminov R.I. A brief history of the antibiotic era: Lessons learned and challenges for the future. Front. Microbiol. 2010; 1:134. doi: 10.3389/fmicb.2010.00134.
3. Duraes F., Pinto M., Sousa E. Medicinal chemistry updates on bacterial efflux pump modulators. Curr. Med. Chem. 2018; 25: 6030–6069.
4. Levy, S. B. & Bonnie, M. Antibacterial resistance worldwide: Causes, challenges and responses. Nat. Med. 2004, 10: S122–S129.
5. Bretonnière, C. et al. Strategies to reduce curative antibiotic therapy in intensive care units (adult and paediatric). Intensive Care Med. 2015. 41: 1181–1196.
6. Macone A.B., Caruso B.K., Leahy R.G., Donatelli J., Weir S., Draper M.P., Tanaka S.K., Levy S.B. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob. Agents Chemother. 2014; 58: 1127–1135
7. Stets R., Popescu M., Gonong J.R., Mitha I., Nseir W., Madej A., Kirsch C., Das A.F., Garrity-Ryan L., Steenbergen J.N., et al. Omadacycline for community-acquired bacterial pneumonia. N. Engl. J. Med. 2019; 380: 517–527
8. Zodvold K.A. Omadacycline : A Review of the Clinical Pharmacokinetics and Pharmacodynamics. Clin Pharmacokinet 2019; (Iv).
9. Moore A.Y. et al. Sarecycline : a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris. 2019; 14: 1235–42.
10. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5): 945–973
11. Hauk L. Acne vulgaris: treatment guidelines from the AAD. Am Fam Physician. 2017;95(11): 740–741.
12. Del Rosso JQ, Gallo RL, Thiboutot D, et al. Status report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society. Part 2: perspectives on antibiotic use and the microbiome and review of microbiologic effects of selected specific therapeutic agents commonly used by dermatologists. J Clin Aesthet Dermatol. 2016;9(5): 11–7.
13. Sinnott SJ, Bhate K, Margolis DJ, et al. Antibiotics and acne: an emerging iceberg of antibiotic resistance? Br J Dermatol. 2016;175(6): 1127–1128
14. 1U.S. Food and Drug Administration. Novel drug approvals for 2018. 2018. https://www.fda.gov/Drugs/Development Approval Process/DrugInnovation/ucm59 2464.htm. Accessed 18 Oct 2018.
15. Allergan Pharmaceuticals International Limited. Seysara (Sarecycline) tablets for oral use: US prescribing information. 2018. https://www.accessdata.fda.gov/.
16. Tetra phase Pharmaceuticals Inc. Xerava (Eravacycline): US prescribing information. 2018. http://www.fda.gov.
17. Zhanel GG, Cheung D, Adam H, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016; 76(5): 567–588.
18. European Medicines Agency. Xerava (Eravacycline): summary of product characteristics. 2018.
19. Nguyen F, Starosta AL, Arenz S, et al. Tetracycline antibiotics and resistance mechanisms. Biol Chem. 2014; 395(5): 559–575.
20. Eljaaly K. et al. Plazomicin : A Novel Aminoglycoside for the Treatment of Resistant Gram - Negative Bacterial Infections. Drugs. 2019. 21.
21. Wagenlehner F.M.E. et al. Once-Daily Plazomicin for Complicated Urinary Tract Infections. N Engl J Med. 2019;729–40. 22. Scott L.J
22. Zhanel GG, Lawson CD, Zelenitsky S, et al. Comparison of the next‐generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther 2012; 10(4): 459– 73.
23. U.S. Food and Drug Administration Antimicrobial Drugs Advisory Committee. FDA briefing document: plazomicin (NDA 210303).
24. Akhilesh Gupta. Plazomicin: A step toward next generation aminoglycosides. Review. Asian J. Res. Pharm. Sci. 2017; 7(3): 173-180.
25. Sinnott SJ, Bhate K, Margolis DJ, et al. Antibiotics and acne: an emerging iceberg of antibiotic resistance? Br J Dermatol. 2016;175(6): 1127–1128